Heat shock protein vaccines: from bench to bedside.
Heat shock proteins (HSPs) are immunogenic, with the specificity of the immune response provided by the peptides that they chaperone. Binding of cell surface receptors by HSPs is central to the elicitation of the innate and adaptive immune responses obtained after vaccination and also plays a physiologic role in cross-priming. These effects of HSPs have been exploited in prophylaxis and therapy of cancer and infectious disease. The data obtained from murine studies have been translated into ongoing clinical trials of cancer of which the most recent results are provided here.
Binder
Robert J
RJ
Center for Immunotherapy of Cancer and Infectious Diseases, Department of Immunology, University of Connecticut School of Medicine, Farmington, Connecticut 06030-1920, USA. rbinder@up.uchc.edu
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D000939:Epitopes / Q000276:immunology*; D006360:Heat-Shock Proteins / Q000276:immunology* / Q000494:pharmacology; D006801:Humans; D007113:Immunity, Innate; D007167:Immunotherapy; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy
D019496:Cancer Vaccines; D000939:Epitopes; D006360:Heat-Shock Proteins